The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter of 2025, with year-over-year revenue ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Now that Thunderbolts is in theaters, it's time watch star Sebastian Stan's best movies like 'A Different Man' and 'Dumb ...

Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

It should have been a typical Dad-movie about outlaws, horses, and the passing of the Wild West into myth. Now it's a ghost ...

Pathos AI, a Chicago biotech led by executives of the healthcare AI group Tempus, is looking at a funding round of up to $400 ...

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the ...

Credit: sanjeri via Getty Images. AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug ...

The platform enables an understanding of the interactions between T cell receptors and their corresponding antigenic epitopes. Credit: THICHA SATAPITANON / Shutterstock. Repertoire Immune Medicines ...

Tempus AI shares were 14% higher, at $49.35, after the company said it has entered into multi-year strategic collaborations with AstraZeneca and Pathos AI.

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in applying artificial intelligence (AI) to healthcare, has announced strategic collaborations with pharmaceutical giant AstraZeneca (LSE/STO/Nasdaq: ...